Antibody therapy for advanced cancer
Part of Cancer clinical trials.
This trial is testing a new type of immunotherapy that uses special antibodies to help your immune system fight cancer. It is for people with advanced cancer who have run out of standard treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of advanced cancer.
- Standard treatments for your cancer type are no longer available or effective for you.
- You are expected to live for at least 3 more months.
- You are able to understand and sign a consent form and follow the study schedule.
- You are in reasonably good physical condition (able to care for yourself and up and about more than 50% of waking hours).
- You are not pregnant or breastfeeding, and you have not had severe side effects from prior cancer treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ABL103 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
This trial tests two new antibody drugs (SSGJ-705 and SSGJ-612), alone or combined with chemotherapy, in patients with advanced cancers that have a protein called HER2. The study aims to see if this combination can shrink tumors and help patients live longer.
This trial tests whether adding a bispecific antibody to chemotherapy before surgery helps treat advanced lung cancer better than a standard antibody. It is for people with stage II-III non-small cell lung cancer who have not had treatment yet.
This trial tests a new study drug, AB821, for people with advanced solid tumors that have stopped responding to standard treatments, especially immunotherapy. The goal is to see if AB821 can shrink tumors or slow their growth.
This trial tests ABX-001, a new immunotherapy, alone or with pembrolizumab, for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. It may help if your tumor has become resistant to previous immunotherapies.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.